HAVCR2 and neoplasm: By day 15, treatment with PD-1 NVs, Tim-3 NVs, and the dual PD-1/Tim-3 NVs resulted in tumor inhibition rates of 33.7%, 50.1%, and 69.0%, respectively (Figure 4B).